{"created":"2023-07-27T06:29:58.467219+00:00","id":14800,"links":{},"metadata":{"_buckets":{"deposit":"e9ec6319-8ef5-418c-803d-010750815d76"},"_deposit":{"created_by":3,"id":"14800","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14800"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014800","sets":["1132:1133:1135"]},"author_link":["22059","22233","26493","26491","640","26492"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2005-06-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"450","bibliographicPageStart":"445","bibliographicVolumeNumber":"31","bibliographic_titles":[{"bibliographic_title":"医療薬学"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We examined the influence of basic drugs and protein variants on the binding disposition of ropivacaine to α_1-acid glycoprotein (AGP). On doing this, we found the values of the competitive inhibition constant (K_i) for dipyridamole, verapamil, lidocaine and disopyramide with respect to the binding of ropivacaine to commercial AGP (70mg/dL) to be 2.1, 5.2, 6.0 and 11.0μM, respectively. Also, there was a strong correlation between the f_u value and the AGP concentration when ropivacaine was added to plasma samples from ten healthy volunteers (r=0.861). Among the volunteers, eight showed F_1S variants and two showed F_1 variants without the S variant of AGP. There was no difference in the f_u value of ropivacaine between these two groups. However, when ropivacaine was added together with dipyridamole, the f_u values of ropivacaine in plasma from volunteers with F_1S variants were clearly higher than those from volunteers without the S variant. When ropivacaine was added together with disopyramide or lidocaine, however, there was no difference in f_u values between these variants. Our results indicate that variability in the effectiveness and/or adverse effects of ropivacaine are caused by changes in f_u as a consequence of changes in AGP concentration. They also suggest that in combination therapy, it is also important to consider the AGP variant-dependence of the inhibitory effect of concomitantly administered drugs","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学大学院自然科学研究科分子作用学","subitem_description_type":"Other"},{"subitem_description":"金沢大学医学部附属病院薬剤部","subitem_description_type":"Other"},{"subitem_description":"金沢大学大学院医学系研究科","subitem_description_type":"Other"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本医療薬学会"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1346-342X","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"石崎, 純子"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"下村, 祥子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"福和, 千恵"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"嶋田, 努"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"横川, 弘一"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"宮本, 謙一"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"PR-ISHIZAKI-J-445.pdf","filesize":[{"value":"981.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PR-ISHIZAKI-J-445.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14800/files/PR-ISHIZAKI-J-445.pdf"},"version_id":"b7d27ab1-1341-4ae2-826b-6715678ef746"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討"},{"subitem_title":"Binding Disposition of Local Anesthetic Ropivacaine to α_1-acid Glycoprotein and Interactions with Co-administered Drugs","subitem_title_language":"en"}]},"item_type_id":"4","owner":"3","path":["1135"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14800","relation_version_is_last":true,"title":["局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:41:01.803637+00:00"}